Titan Biotech Intrinsic Value
Titan Biotech intrinsic value. Titan Biotech (TITANBIO) median intrinsic value is ₹204.00 from 10 valuation models (range ₹115–₹490), vs current price ₹383.20 — -46.8% downside (Trading Above Calculated Value), margin of safety -87.8%. Read TITANBIO dividend payout details for the complete payout history and dividend yield track record.
TITANBIO Valuation Methods Summary — DCF, Graham Number & P/E
Titan Biotech intrinsic value across 10 models vs current price ₹383.20 — upside/downside and value range per method. Compare with TITANBIO DCF valuation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹114.96 | ₹91.97 - ₹137.95 | -70.0% | EPS: ₹6.52, Sector P/E: 12x |
| Book Value Method | asset | ₹227.50 | ₹204.75 - ₹250.25 | -40.6% | Book Value/Share: ₹227.50, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹204.00 | ₹183.60 - ₹224.40 | -46.8% | Revenue/Share: ₹255.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹360.00 | ₹324.00 - ₹396.00 | -6.1% | EBITDA: ₹48.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹391.99 | ₹313.59 - ₹470.39 | +2.3% | CF Growth: 8.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹114.96 | ₹103.46 - ₹126.46 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹114.96 | ₹103.46 - ₹126.46 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹490.00 | ₹441.00 - ₹539.00 | +27.9% | ROE: 15.4%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹182.69 | ₹164.42 - ₹200.96 | -52.3% | EPS: ₹6.52, BVPS: ₹227.50 |
| Dividend Yield Method | dividend | ₹114.96 | ₹103.46 - ₹126.46 | -70.0% | DPS: ₹0.50, Target Yield: 3.5% |
TITANBIO Intrinsic Value vs Market Price — All Valuation Models
Titan Biotech fair value range ₹115–₹490 vs current market price ₹383.20 across 10 valuation models. For current market price and key ratios, visit Titan Biotech share price chart.
TITANBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Titan Biotech median intrinsic value ₹204.00, current price ₹383.20 — Trading Above Calculated Value by 46.8%, margin of safety -87.8%.
What is the intrinsic value of TITANBIO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Titan Biotech (TITANBIO) is ₹204.00 (median value). With the current market price of ₹383.20, this represents a -46.8% variance from our estimated fair value.
The valuation range spans from ₹114.96 to ₹490.00, indicating ₹114.96 - ₹490.00.
Is TITANBIO undervalued or overvalued?
Based on our multi-method analysis, Titan Biotech (TITANBIO) appears to be trading above calculated value by approximately 46.8%.
TITANBIO Financial Health — Key Ratios vs Industry Benchmarks
Titan Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.17 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.95x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
TITANBIO Cash Flow Quality — Operating & Free Cash Flow
Titan Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹30 Cr | ₹14 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹20 Cr | ₹15 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹21 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹21 Cr | ₹11 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹22 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |